Drug Database
CO

COVID-19 vaccine (S 268019 / S268019 / Covgoze)

✓ Approved

Shionogi · Recombinant Proteins · Recombinant Proteins

What is COVID-19 vaccine?

COVID-19 vaccine is a recombinant proteins developed by Shionogi. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesS 268019, S268019, Covgoze
CompanyShionogi
Drug ClassRecombinant Proteins, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Shionogi

Therapeutic Indications

COVID-19 vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsCOVID-19✓ Approved

Related Research Articles

PubMedKidney research and clinical practice2026-10-22

Clinical effects of third doses of mRNA COVID-19 vaccines among hemodialysis patients: a nationwide retrospective cohort study.

Cho AJin A, Jeong Seon A SA, Seo Yu Bin YB, Park Hayne Cho HC et al.

Evidence on the effectiveness of third-dose messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccination during the Omicron-dominant period in Asian hemodialysis (HD) patients remains limited. We evaluated the clinical effectiveness of a third mRNA vaccine dose against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality in Korean HD patients. Using the Korea Disease Control and Prevention Agency-National Health Insurance Service database, we conducted a nationwide cohort study of HD patients aged ≥18 years who received two or three doses of BNT162b2 or mRNA-1273 before January 16, 2022. Study outcomes were SARS-CoV-2 infection, hospitalization, and death. Cox proportional hazards models were used to assess the associations between third-dose vaccination and clinical outcomes. Among 66,389 HD patients (mean age, 65.7 ± 12.9 years; 60.5% male), 55,125 (83.0%) received three vaccine doses and 11,264 (17.0%) received two doses. Receipt of three doses was associated with a significantly lower risk of SARS-CoV-2 infection (adjusted hazard ratio [aHR], 0.58; 95% confidence interval [CI], 0.56-0.60). Among 17,886 patients with SARS-CoV-2 infection, third-dose vaccine recipients had a lower risk of hospitalization (aHR, 0.65; 95% CI, 0.62-0.70) and 30-day mortality (aHR, 0.35; 95% CI, 0.30-0.41) compared with those who received two doses. Receipt of mRNA-1273 as the third dose was associated with lower observed risks of infection and hospitalization than receipt of BNT162b2. A third dose of an mRNA COVID-19 vaccine was associated with lower risks of SARS-CoV-2 infection, hospitalization, and mortality among HD patients during the Omicron-dominant period. These findings support the clinical importance of booster vaccination in this high-risk population.

PMID 42902884
Read full article →
PubMedUgeskrift for laeger2026-10-22

[Overweight and lung diseases].

Lange Jakob Klyver JK, Plovsing Ronni Thermann Reitz RTR, Lange Peter P, Iepsen Ulrik Winning UW

Overweight increases dyspnea and cough. Overweight patients with asthma experience more symptoms, frequent exacerbations and have poorer effects of asthma medications. In COPD, light and moderate overweight are associated with a better prognosis, whereas severe overweight is not. Similar protective effects of overweight have been reported in severe bacterial pneumonia and ARDS, but not in COVID-19 or severe influenza. This review finds that the beneficial effects of weight loss are best documented in asthma and in respiratory sleep-related disorders.

PMID 42902768
Read full article →
PubMedRevue medicale suisse2026-10-22

[Proximity psychology : clinical presence and perspectives].

Rombaldi Sylvie S, Haenni Chevalley Catherine C, Leuzzi Boaretto Nadia N

Proximity psychology has developed in hospital settings as a continuation of institutional psychiatry, community psychology, and, more recently, emergency psychology implemented during the Covid-19 pandemic. It is characterized by a discreet and regular clinical presence within teams, aimed at supporting subjectivity, creativity, and collective bonds in a context marked by multiple challenges. By fostering spaces for dialogue and symbolization, it enables staff members to preserve their psychological vitality and to act as authors of their own practice. For the institution, it represents both a sustainable investment in occupational health and an ethical form of resistance. The limits of this activity are linked to various institutional challenges.

PMID 42902969
Read full article →
PubMedFrontiers in public health2026-10-22

Ambient air pollution and meteorological factors associated with hand, foot, and mouth disease risk in Shenzhen, China: a time-series study.

Jiang Shuai S, Liu Jingwen J, Ji Jiajia J, Cheng Yanpeng Y et al.

In China, hand, foot, and mouth disease (HFMD) persists as a prevalent infectious disease with high transmissibility. Nevertheless, the link between environmental determinants and HFMD incidence has not been fully elucidated. The study assessed associations between air pollution, meteorological conditions, and HFMD incidence in Shenzhen, China, while also evaluating shifts in these associations before and after the Enterovirus 71 vaccine and during the COVID-19 epidemic. Daily data on HFMD cases, air pollutants (such as PM2.5, PM10, SO2, NO2, CO, and O3), and meteorological variables (including mean temperature, relative humidity, atmospheric pressure, and wind speed) were collected for the period from 2013 to 2022. Associations were assessed using distributed lag non-linear models (DLNM), accounting for immediate and delayed effects. Spearman correlation analysis showed that HFMD was positively correlated with SO₂, mean temperature, relative humidity, and wind speed, and negatively with PM₂.₅, PM₁₀, NO₂, CO, and atmospheric pressure. DLNM models revealed that SO₂ and CO both elevated cumulative risk at extremely high concentrations, with SO₂ showing delayed effects. However, SO₂ unexpectedly displayed protective effects in single-lag analysis. NO₂ exhibited a U-shaped risk at extreme concentrations despite an overall decreasing trend. O₃ showed dual peaks, with protective effects at extremely high concentrations after lag 1. PM2.5 and PM10 showed risk peaks at low concentrations but protective effects at extremely high concentrations. Temperature exhibited a dual-peak risk pattern at extremely low and extremely high temperatures, with extreme heat producing sustained effects and extreme cold shorter-lived risk. HFMD risk increased under conditions of extremely high humidity. In general, the risk associated with atmospheric pressure rose as pressure levels increased, and asymmetric lagged effects were observed at both low- and high-concentration extremes. Extremely high wind speed causing short-term harm and extremely low wind speed leading to delayed cumulative risk. Meteorological factors exhibit more consistent associations than air pollutants. Mean temperature showed a dual-peak distribution with persistent effects from high temperatures, while atmospheric pressure presented long-lasting impacts of low pressure. There is a positive correlation between relative humidity and the incidence of HFMD. Air pollutants showed inconsistent associations with HFMD. These findings support targeted public health interventions for meteorological factors.

PMID 42903182
Read full article →
PubMedFrontiers in immunology2026-10-22

A subunit vaccine protects A129 mice from death and joint swelling against lethal Chikungunya virus challenge.

Li Jiangfan J, Fang Ting T, Song Liyuan L, Qiang Li L et al.

Chikungunya virus (CHIKV) is primarily transmitted to humans through bites of infected Aedes mosquitoes, causing febrile illness as well as acute or chronic arthritis. With increasing reports in previously non-endemic regions, it poses an emerging threat to public health and a growing risk to travelers. Despite the recent approval of live-attenuated and virus-like particle-based vaccines, a safe, efficacious, and cost-effective vaccine remains urgently needed. The envelope glycoproteins E1 and E2, which play crucial roles in viral attachment and entry, are the major immunodominant structural proteins and can effectively elicit protective antibodies. We engineered mammalian cells to produce the ectodomains of the E1 and E2 glycoproteins and evaluated the protective efficacy of the resulting vaccine formulations in vivo. A two-dose vaccination regimen elicited high levels of antibodies and provided full protection against lethal challenge in A129 mice, preventing both death and joint swelling. These findings demonstrate the potential of this vaccine candidate against CHIKV and warrant its further development.

PMID 42903135
Read full article →
PubMedEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2026-10-22

[Strategies to address vaccine hesitancy in Brazil: evidence synthesis].

Marques Ana Paula da Costa APDC, Gubert Vanessa Terezinha VT, Dias Adriano da Costa ADC, Gasparoto Antonio Luiz Dal Bello ALDB et al.

PMID 42903010
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about COVID-19 vaccine